Biogen Pharmachem Industries Ltd has closed its trading window for dealing in the company's securities effective from July 1, 2026. The restriction will remain in place until 48 hours after the announcement of the unaudited financial results for the first quarter ended June 30, 2026. This action is in compliance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, and the company's internal Code of Conduct for Prohibition of Insider Trading.

The closure of the trading window is a standard procedure implemented to prevent insider trading during the period when financial information is being finalized and is yet to be made public. The company stated that the date for the proposed board meeting to consider the unaudited financial results for the first quarter will be informed in due course.

Key Details

The intimation was formally addressed to the Department of Corporate Services at BSE Limited. The letter was signed by Kelash Bunkar, Director of Biogen Pharmachem Industries Ltd, confirming the implementation of the trading ban.

Rama Shiva Lease Finance Private Limited has submitted a disclosure to BSE Limited regarding the sale of shares in Biogen Pharmachem Industries Limited . The filing was made in compliance with Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The acquirer, which is not part of the promoter or promoter group of the target company, sold 4,75,00,000 shares carrying voting rights. This transaction was executed via the open market on May 18, 2026. The shares sold represent 5.26% of the company's total share capital and voting rights.

Prior to this sale, Rama Shiva Lease Finance Private Limited held 8,40,00,000 shares, which accounted for 9.31% of the total paid-up share capital. Following the sale of the 4.75 crore shares, the acquirer's remaining holding has decreased to 3,65,00,000 shares. This revised holding constitutes 4.04% of the total share capital and voting rights of Biogen Pharmachem Industries Limited.

Shareholding Details

The disclosure outlines the changes in the acquirer's shareholding pattern, detailing the number of shares held before and after the transaction. The total equity share capital of the target company remains unchanged at Rs. 90,26,03,000, divided into 90,26,03,000 equity shares of Rs. 2 each.

The acquirer confirmed that there are no shares held under encumbrance, nor are there any warrants or convertible securities that entitle the acquirer to receive additional voting rights. The total diluted share capital of the company remains at 90,26,03,000 equity shares.